Bio-Techne(TECH) Prnewswire·2025-01-10 12:00Product Portfolio Expansion - The company has launched a new portfolio of designer proteins engineered using advanced AI-based design platforms and protein evolutionary workflows [4] - The expanded portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable, and Wnt/RSPO1, Wnt/RSPO2, and Wnt/RSPO3 Agonist proteins [4] - These proteins are designed to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion [2] Technological Innovation - The company leverages generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design [2] - The new proteins feature tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability [2] - The FGF basic Heat Stable protein is available in both RUO and GMP formats to support cell therapy manufacturing and advanced research [3] Market Leadership - The company continues to lead in delivering disruptive innovations to the life sciences and therapeutic development communities [5] - The designer proteins are part of the company's market-leading R&D Systems branded portfolio of proteins [5] Company Overview - The company is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities [6] - It generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide [6]